Approved, in combination with dexamethasone, for adults with relapsed or refractory multiple myeloma (RRMM) after at least four prior therapies and refractory to two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 antibody (“penta-refractory” or “triple-class refractory” disease) — and, in combination with bortezomib and dexamethasone, for myeloma after one or more prior therapies. Also approved for certain diffuse large B-cell lymphoma (DLBCL) patients.